RUXIENCE is a brand name for rituximab-pvvr, a biosimilar to the original rituximab, which is a monoclonal antibody used in the treatment of certain autoimmune diseases and types of cancer. Specifically, it is indicated for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. RUXIENCE works by targeting the CD20 protein found on the surface of B cells, leading to their destruction. This action helps to reduce the harmful effects of diseases that are characterized by an overactive, dysfunctional immune system or by the proliferation of abnormal B cells. As a biosimilar, RUXIENCE has been shown to have no clinically meaningful differences in purity, potency, and safety compared to its reference product, offering a potentially more cost-effective treatment option for patients.